Literature DB >> 23804235

Recombinant thrombomodulin of different domains for pharmaceutical, biomedical, and cell transplantation applications.

Lin Wang1, Rui Jiang, Xue-Long Sun.   

Abstract

Thrombomodulin (TM) is a membrane glycoprotein mainly expressed by vascular endothelial cells and is involved in many physiological and pathological processes, such as coagulation, inflammation, cancer development, and embryogenesis. Human TM consists of 557 amino acids divided into five distinct domains: N-terminal lectin-like domain (designated as TMD1); six epidermal growth factor (EGF)-like domain (TMD2); Ser/Thr-rich domain (TMD3); transmembrane domain (TMD4); and cytoplasmic tail domain (TMD5). The different domains are responsible for different biological functions of TM. In the past decades, various domains of TM have been cloned and expressed for TM structural and functional study. Further, recombinant TMs of different domains show promising antithrombotic and anti-inflammatory activity in both rodents and primates and a recombinant soluble TM has been approved for therapeutic application. This review highlights recombinant TMs of diverse structures and their biological functions, as well as the complex interactions of TM with factors involved in the related biological processes. Particularly, recent advances in exploring recombinant TM of different domains for pharmaceutical, biomedical, and cell transplantation applications are summarized.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-inflammation; antithrombosis; endothelial cell; recombinant; thrombomodulin

Mesh:

Substances:

Year:  2013        PMID: 23804235     DOI: 10.1002/med.21294

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  7 in total

1.  Thrombomodulin Protects Against Bacterial Keratitis, Is Anti-Inflammatory, but Not Angiogenic.

Authors:  Sharon A McClellan; Sandamali A Ekanayaka; Cui Li; Xiaoyu Jiang; Ronald P Barrett; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

2.  End-point modification of recombinant thrombomodulin with enhanced stability and anticoagulant activity.

Authors:  Xia Liu; Mallorie Boron; Yu Zhao; Xue-Long Sun
Journal:  Eur J Pharm Sci       Date:  2019-09-09       Impact factor: 4.384

3.  Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination.

Authors:  Wei Dong; Hongjie Wang; Khurrum Shahzad; Fabian Bock; Moh'd Mohanad Al-Dabet; Satish Ranjan; Juliane Wolter; Shrey Kohli; Juliane Hoffmann; Vishnu Mukund Dhople; Cheng Zhu; Jonathan A Lindquist; Charles T Esmon; Elisabeth Gröne; Herman-Josef Gröne; Thati Madhusudhan; Peter R Mertens; Dirk Schlüter; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2015-05-26       Impact factor: 10.121

4.  Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulation-A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients.

Authors:  Michael Hultström; Karin Fromell; Anders Larsson; Barbro Persson; Bo Nilsson; Susan E Quaggin; Christer Betsholtz; Robert Frithiof; Miklos Lipcsey; Marie Jeansson
Journal:  Biomedicines       Date:  2022-06-06

5.  The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.

Authors:  Masato Yoshihara; Kaname Uno; Sho Tano; Michinori Mayama; Mayu Ukai; Shinya Kondo; Tetsuya Kokabu; Yasuyuki Kishigami; Hidenori Oguchi
Journal:  Crit Care       Date:  2015-10-20       Impact factor: 9.097

6.  Layer-by-Layer Heparinization of the Cell Surface by Using Heparin-Binding Peptide Functionalized Human Serum Albumin.

Authors:  Guowei Song; Yaning Hu; Yusheng Liu; Rui Jiang
Journal:  Materials (Basel)       Date:  2018-05-20       Impact factor: 3.623

7.  Effects of sevoflurane and propofol anesthesia on intraoperative endothelial cell function in patients undergoing laparoscopic cholecystectomy.

Authors:  Yu Fan; Hao Wang; Qi Ma
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.